These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20031730)

  • 21. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
    Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Marzocchi A; Saia F; Piovaccari G; Manari A; Aurier E; Benassi A; Cremonesi A; Percoco G; Varani E; Magnavacchi P; Guastaroba P; Grilli R; Maresta A
    Circulation; 2007 Jun; 115(25):3181-8. PubMed ID: 17562952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
    Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
    JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
    Stone GW; Ellis SG; Colombo A; Dawkins KD; Grube E; Cutlip DE; Friedman M; Baim DS; Koglin J
    Circulation; 2007 Jun; 115(22):2842-7. PubMed ID: 17515458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients.
    Flores-Ríos X; Marzoa-Rivas R; Abugattás-de Torres JP; Piñón-Esteban P; Aldama-López G; Salgado-Fernández J; Calviño-Santos R; Vázquez-Rodríguez JM; Vázquez-González N; Castro-Beiras A
    Am Heart J; 2008 Apr; 155(4):648-53. PubMed ID: 18371471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up on a large cohort of "full-metal jacket" percutaneous coronary intervention procedures.
    Sharp AS; Latib A; Ielasi A; Larosa C; Godino C; Saolini M; Magni V; Gerber RT; Montorfano M; Carlino M; Michev I; Chieffo A; Colombo A
    Circ Cardiovasc Interv; 2009 Oct; 2(5):416-22. PubMed ID: 20031751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel-eluting stents for the treatment of complex coronary lesions: immediate and 12-month results.
    Sheiban I; Ballari GP; Moretti C; Marra WG; Meliga E; Omedè P; Sciuto F; Trevi GP
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):582-8. PubMed ID: 17667028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
    EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry.
    Machecourt J; Danchin N; Lablanche JM; Fauvel JM; Bonnet JL; Marliere S; Foote A; Quesada JL; Eltchaninoff H; Vanzetto G;
    J Am Coll Cardiol; 2007 Aug; 50(6):501-8. PubMed ID: 17678732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
    Brilakis ES; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    J Interv Cardiol; 2011 Aug; 24(4):342-50. PubMed ID: 21492221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
    Garg P; Mauri L
    Curr Opin Cardiol; 2007 Nov; 22(6):565-71. PubMed ID: 17921745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.